Evaluation of intraosteoblastic activity of dalbavancin against Staphylococcus aureus in an ex vivo model of bone cell infection

Archive ouverte

Chauvelot, Pierre | Dupieux-Chabert, Céline | Abad, Lélia | Souche, Aubin | Ferry, Tristan | Josse, Jérôme | Laurent, Frédéric | Valour, Florent | Perpoint, Thomas | Miailhes, Patrick | Ader, Florence | Roux, Sandrine | Becker, Agathe | Triffault-Fillit, Claire | Conrad, Anne | Pouderoux, Cécile | Benech, Nicolas | Chabert, Paul | Braun, Evelyne | Chidiac, Christian | Lustig, Sébastien | Servien, Elvire | Batailler, Cécile | Gunst, Stanislas | Schimdt, Axel | Malatray, Matthieu | Sappey-Marinier, Eliott | Michel-Henry, Fessy | Viste, Anthony | Jean-Luc, Besse | Chaudier, Philippe | Louboutin, Lucie | Ode, Quentin | van Haecke, Adrien | Mercier, Marcelle | Belgaid, Vincent | Walch, Arnaud | Martres, Sébastien | Trouillet, Franck | Heery, Yannick | Barrey, Cédric | Mojallal, Ali | Brosset, Sophie | Hanriat, Camille | Person, Philippe Céruse | Fuchsmann, Carine | Daveau, Clémentine | Blanc, Jacques | Gleizal, Arnaud | Daurade, Mathieu | Bourlet, Jérôme | Aubrun, Frédéric | Dziadzko, Mikhail | Macabéo, Caroline | Laurent, Frederic | Beraut, Laetitia | Roussel-Gaillard, Tiphaine | Kolenda, Camille | Craighero, Fabien | Boussel, Loic | Pialat, Jean-Baptiste | Morelec, Isabelle | Tod, Michel | Gagnieu, Marie-Claude | Goutelle, Sylvain | Mabrut, Eugénie

Edité par CCSD ; Oxford University Press (OUP) -

International audience. Abstract Objectives Long-acting lipoglycopeptides are promising therapeutic options in Staphylococcus aureus bone and joint infections (BJIs). This study evaluated the ability of dalbavancin to eradicate the intraosteoblastic reservoir of S. aureus, associated with BJI chronicity. Methods Osteoblastic cells were infected with a standardized inoculum of the S. aureus reference strain HG001 and incubated for 24 h with dalbavancin, vancomycin or rifampicin using the MIC, 10×MIC, 100×MIC and/or the intraosseous concentrations reached using standard therapeutic doses (i.e. vancomycin, 10 mg/L; rifampicin, 2 mg/L; and dalbavancin, 6 mg/L). The remaining intracellular bacteria were quantified by plating cell lysates. Results MICs of dalbavancin, vancomycin and rifampicin were 0.125, 1 and 0.004 mg/L, respectively. Dalbavancin significantly reduced the intracellular inoculum of S. aureus starting at a concentration equal to the MIC, with a significant dose effect, ranging from a reduction of 31.4% (95% CI = 17.6%–45.2%) at MIC to 51.6% (95% CI = 39.8%–63.4%) at 100×MIC compared with untreated cells. Of note, dalbavancin was the only molecule to significantly reduce the intraosteoblastic inoculum at low concentration (MIC). At intraosseous concentrations, dalbavancin reduced the intracellular inoculum by 49.6% (95% CI = 45.1%–54.1%) compared with untreated cells (P < 0.001), with no significant difference compared with vancomycin (38.1%; 95% CI = 19.2%–57.0%; P = 0.646), and was less efficient than rifampicin (69.0%; 95% CI = 63.2-74.8; P < 0.001). Conclusions Dalbavancin was able to decrease the intraosteoblastic S. aureus inoculum by 50% at intraosseous concentrations reached during standard human therapeutic dosing, with no difference compared with vancomycin, and remained less efficient than rifampicin. However, it was the only molecule significantly active at low concentration.

Consulter en ligne

Suggestions

Du même auteur

Evaluation of intraosteoblastic activity of dalbavancin against Staphylococcus aureus in an ex vivo model of bone cell infection

Archive ouverte | Chauvelot, Pierre | CCSD

International audience. Abstract Objectives Long-acting lipoglycopeptides are promising therapeutic options in Staphylococcus aureus bone and joint infections (BJIs). This study evaluated the ability of dalbavancin ...

Population pharmacokinetics of daptomycin in patients with bone and joint infection: minimal effect of rifampicin co-administration and confirmation of a sex difference

Archive ouverte | Garreau, Romain | CCSD

International audience. Background Daptomycin is increasingly used in the treatment of bone and joint infection (BJI), but its pharmacokinetics (PK) and dosage requirements have not been thoroughly investigated in t...

Implementation of a complex bone and joint infection phage therapy centre in France: lessons to be learned after 4 years' experience

Archive ouverte | Ferry, Tristan | CCSD

International audience

Chargement des enrichissements...